{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:07:41Z","timestamp":1789664861984,"version":"4.0.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The purpose of the present study was to evaluate outcomes with a combination of stereotactic body radiation therapy (SBRT) for patients with hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      The present retrospective study included 46 patients with 1\u20133 liver lesions with portal vein tumor thrombosis (PVTT) in 27 treated with definitive, consolidative, or salvage SBRT. The patients had Barcelona Clinic Liver Cancer (BCLC) stage A, B, or C disease (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 44) with new, residual, progressive, or recurrent lesions with prior liver-directed and\/or systemic therapy (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 37). The median combined maximum diameter of the lesions was 7.48 cm (range, 1.55\u201316.5 cm). The dose fractionation for SBRT was 24\u201350 Gy in 5\u20138 fractions (median = 30 Gy in 6 fractions) with volumetric modulated arc technique on linear accelerator. Systemic treatment with sorafenib, lenvatinib, and\/or nivolumab was given in 35 patients. Liver-directed interventional treatment after SBRT was given in 10 patients. Treatment response was evaluated as per mRECIST with or without Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST), and Kaplan\u2013Meier survival analysis was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patient-reported relief in symptoms was observed in 59.4% after SBRT. Of 46, 27 (58.7%) had decreased serum tumor markers with AFP and\/or PIVKA-II at 3 months after SBRT with systemic treatment. The median overall survival (OS) was 21.4 months (95% CI: 14.3\u201328.5 months) after the index cancer diagnosis. The 6-month, 1-year, 2-year, and 3-year OS rates after diagnosis were 84.8%, 60.6%, 44.7%, and 28.2%, respectively. The median OS was 25.3 months versus 10.9 months in patients without versus with PVTT, respectively. Early response at 3\u20134 months after SBRT with systemic therapy (complete or partial (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 29) versus stable or progressive (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 17)) showed an independent association with OS (P \u2264 0.001, hazard ratio (HR) 3.88, 95% CI: 1.94\u20137.77). The estimated 1-year and 2-year local control rates in all patients were 94.1% and 89.6% after SBRT with systemic therapy. One patient had conversion surgery. Grade 3 hepatic toxicity during SBRT was 10.9%. Liver dysfunction with a Child-Pugh score of 2 or more points within 3 months after SBRT with systemic therapy was noted in 27.3% of patients. Late gastrointestinal toxicity was observed in 1 patient (2.17%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The present study suggested that a combination of radiotherapy with other liver-directed and\/or systemic treatments is associated with favorable disease control and prolongation of survival in patients with early to advanced-stage HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2351_24","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:00:22Z","timestamp":1758906022000},"page":"1013-1025","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes with combination of stereotactic body radiation therapy in patients with hepatocellular carcinoma"],"prefix":"10.4103","volume":"21","author":[{"given":"Puja","family":"Sahai","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aprajita","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit P.","family":"Solanky","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishak","family":"Jawahar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangu S.","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasim","family":"Jaleel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Jagya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saggere M.","family":"Shasthry","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanuman P.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"R3-20250929","first-page":"171","article-title":"The role of stereotactic body radiotherapy in hepatocellular carcinoma:Guidelines and evidences","volume":"2","author":"Hu","year":"2022","journal-title":"J Natl Cancer Cent"},{"key":"R4-20250929","first-page":"100740","article-title":"Do we have a winner?Advocating for SBRT in HCC management","volume":"45","author":"Safavi","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"R5-20250929","first-page":"e43026","article-title":"The demographic and clinicopathological characteristics of hepatopancreatobiliary cancers from a specialized center in India","volume":"15","author":"Sahai","year":"2023","journal-title":"Cureus"},{"key":"R6-20250929","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma:An update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"R7-20250929","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma:2018 practice guidance by the American Association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"R8-20250929","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"Suppl 1","key":"R9-20250929","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST:Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R10-20250929","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers:An ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"R11-20250929","doi-asserted-by":"crossref","first-page":"109912","DOI":"10.1016\/j.radonc.2023.109912","article-title":"A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors","volume":"189","author":"Bordeau","year":"2023","journal-title":"Radiother Oncol"},{"key":"R12-20250929","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jrr\/rrae006","article-title":"Albumin-bilirubin score is a useful predictor of worsening liver reserve after stereotactic body radiation therapy in elderly Japanese patients with hepatocellular carcinoma","volume":"65","author":"Yoshino","year":"2024","journal-title":"J Radiat Res"},{"key":"R13-20250929","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.clon.2023.08.012","article-title":"Definitive stereotactic body radiation therapy in early-stage solitary hepatocellular carcinoma:An Australian multi-institutional review of outcomes","volume":"35","author":"Liu","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R14-20250929","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.clon.2020.04.004","article-title":"Efficacy and toxicity of stereotactic body radiotherapy for early to advanced stage hepatocellular carcinoma \u2013Initial experience from an Australian liver cancer service","volume":"32","author":"Liu","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R15-20250929","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma:Meta-analysis and international stereotactic radiosurgery society practice guidelines","volume":"118","author":"Bae","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20250929","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/1754-9485.13794","article-title":"Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma","volume":"69","author":"Song","year":"2025","journal-title":"J Med Imaging Radiat Oncol"},{"key":"R17-20250929","first-page":"100878","article-title":"Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma","volume":"49","author":"den Toom","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"R18-20250929","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/ijmr.ijmr_1171_21","article-title":"Evaluation of liver segmental dose threshold for hepatocyte regeneration following liver stereotactic body radiation therapy","volume":"159","author":"George","year":"2024","journal-title":"Indian J Med Res"},{"key":"R19-20250929","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/PPO.0000000000000679","article-title":"Evolution of response-based radiotherapy for hepatocellular cancer","volume":"29","author":"Elaimy","year":"2023","journal-title":"Cancer J"},{"key":"R20-20250929","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2017.2303","article-title":"Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage:A phase 2 clinical trial","volume":"4","author":"Feng","year":"2018","journal-title":"JAMA Oncol"},{"key":"R21-20250929","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2019.07.027","article-title":"A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy","volume":"141","author":"Jackson","year":"2019","journal-title":"Radiother Oncol"},{"key":"R22-20250929","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijrobp.2017.09.032","article-title":"Using indocyanine green extraction to predict liver function after stereotactic body radiation therapy for hepatocellular carcinoma","volume":"100","author":"Suresh","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20250929","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ijrobp.2018.04.011","article-title":"Baseline albumin-bilirubin (ALBI) score in Western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT)","volume":"101","author":"Murray","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-20250929","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13014-019-1251-y","article-title":"Albumin\u2013bilirubin (ALBI) versus child-turcotte-pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy","volume":"14","author":"Su","year":"2019","journal-title":"Radiat Oncol"},{"key":"R25-20250929","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijrobp.2017.04.036","article-title":"Comparison between child-turcotte-pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiation therapy","volume":"99","author":"Lo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20250929","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijrobp.2021.04.012","article-title":"The potential for midtreatment albumin-bilirubin (ALBI) score to individualize liver stereotactic body radiation therapy","volume":"111","author":"Jackson","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-20250929","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4103\/sjg.sjg_195_24","article-title":"Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma:A single institutional clinical experience","volume":"30","author":"Park","year":"2024","journal-title":"Saudi J Gastroenterol"},{"key":"R28-20250929","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma:The NRG oncology\/RTOG 1112 Phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"R29-20250929","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.31557\/APJCP.2024.25.9.3073","article-title":"Comparison between trans-arterial chemoembolization followed by stereotactic body radiation therapy and trans-arterial chemoembolization alone in BCLC stage B hepatocellular carcinoma:A pilot study","volume":"25","author":"Saad","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"key":"R30-20250929","doi-asserted-by":"crossref","first-page":"104191","DOI":"10.1016\/j.critrevonc.2023.104191","article-title":"Combination treatment of HCC with SBRT and immune checkpoint inhibition","volume":"192","author":"Podesta","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"R31-20250929","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00261-024-04620-1","article-title":"Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus:A retrospective cohort study","volume":"50","author":"Tan","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"R32-20250929","doi-asserted-by":"crossref","first-page":"e256931","DOI":"10.1136\/bcr-2023-256931","article-title":"Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy","volume":"16","author":"Bidarmaghz","year":"2023","journal-title":"BMJ Case Rep"},{"key":"R33-20250929","doi-asserted-by":"crossref","first-page":"111077","DOI":"10.1016\/j.ejrad.2023.111077","article-title":"Longitudinal assessment of hepatocellular carcinoma response to stereotactic body radiation using gadoxetate-enhanced MRI:A case series","volume":"167","author":"Sharma","year":"2023","journal-title":"Eur J Radiol"},{"key":"R34-20250929","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.12998\/wjcc.v12.i16.2847","article-title":"Conversion therapy of a giant hepatocellular carcinoma with portal vein thrombus and inferior vena cava thrombus:A case report and review of literature","volume":"12","author":"Song","year":"2024","journal-title":"World J Clin Cases"},{"key":"R35-20250929","doi-asserted-by":"crossref","first-page":"e2415998","DOI":"10.1001\/jamanetworkopen.2024.15998","article-title":"Stereotactic body radiotherapy and liver transplant for liver cancer:A nonrandomized controlled trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R36-20250929","first-page":"100465","article-title":"Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy","volume":"39","author":"Wu","year":"2022","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2351_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:02Z","timestamp":1787067842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2351_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2351_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}